Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06634589 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

A Phase 1 study of B-cell Lymphoma and Refractory Cancer, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
20
Study locations

NCT06634589 is a Phase 1 study of B-cell Lymphoma and Refractory Cancer that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 80 participants, roughly in line with the 88-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06634589, a Phase 1 study of B-cell Lymphoma and Refractory Cancer, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.

Conditions Studied

B-cell Lymphoma Refractory Cancer Relapsed Cancer B-cell Malignancy

Interventions

  • DRUG Zanubrutinib
  • DRUG BGB-16673
  • DRUG Sonrotoclax
  • DRUG Mosunetuzumab
  • DRUG Glofitamab

Study Locations (20)

New York

  • Icahn School of Medicine At Mount Sinai - New York
  • Columbia University Medical Center - New York
  • Weill Cornell Medical College Newyork Presbyterian Hospital - New York
  • Memorial Sloan Kettering Cancer Center Mskcc - New York
  • University of Rochester - Rochester

Florida

  • Mayo Clinic Jacksonville - Jacksonville
  • Moffitt Cancer Center - Tampa

Wisconsin

  • University of Wisconsin - Madison
  • Medical College of Wisconsin - Milwaukee

Arizona

  • Mayo Clinic Phoenix - Phoenix

California

  • University of Southern Californianorris Comprehensive - Los Angeles

Kansas

  • The University of Kansas Cancer Center - Westwood

Minnesota

  • Mayo Clinic Rochester - Rochester

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-11-27
Est. Completion 2029-12-02
Phase Phase 1

Sponsor

BeOne Medicines

29 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06634589

The ClinicalTrials.gov registry entry for NCT06634589 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 88-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target. The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with B-cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Zanubrutinib is the first listed.

NCT06634589 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Florida, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT06634589 about?

NCT06634589 is a clinical study titled "A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies". The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separat...

What is the current status of trial NCT06634589?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-11-27. Estimated completion is 2029-12-02.

What conditions does trial NCT06634589 study?

This clinical trial studies the following conditions: B-cell Lymphoma, Refractory Cancer, Relapsed Cancer, B-cell Malignancy.

What interventions are being tested in trial NCT06634589?

The interventions under investigation include: Zanubrutinib (DRUG), BGB-16673 (DRUG), Sonrotoclax (DRUG), Mosunetuzumab (DRUG), Glofitamab (DRUG).

Who is sponsoring clinical trial NCT06634589?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06634589 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for B-cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

B-cell Lymphoma

All registered trials for this condition

Refractory Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.